Stock AnalizNovo Nordisk A S NVO
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Novo Nordisk A S (NVO) is a healthcare company listed in the US with a market value of about $184.3B. In the twelve months to September 30, 2026 it had revenue of $49.2B and net income of $16.7B, a net margin of 33.9%.
Its overall Stock Analiz score is 3.4 out of 5 (good). The strongest part is track record (5/5); the weakest is value (3/5).
Key numbers: a P/E of 11.1, a price to free cash flow of 27.8, 5-year revenue growth of 18% a year, a 5-year average ROIC of 47%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 37% below the current price.
Score: 3.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.2B | $48.6B | $40.5B | $34.4B | $25.4B | $21.4B | $20.9B | $18.3B |
| Net income | $16.7B | $16.1B | $14.1B | $12.4B | $8.0B | $7.3B | $6.9B | $5.9B |
| Free cash flow | $6.6B | $9.3B | $10.3B | $12.3B | $9.6B | $7.4B | $7.6B | $5.7B |
| EPS (diluted) | $3.76 | $3.64 | $3.18 | $2.80 | $1.80 | $1.64 | $1.57 | $1.32 |
| Net margin | 33.9% | 33.1% | 34.8% | 36.0% | 31.4% | 33.9% | 33.2% | 31.9% |
| ROIC | — | 30.8% | 41.4% | 61.4% | 55.0% | 48.7% | 58.3% | 67.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Novo Nordisk A S’s P/E ratio?
About 11.1, based on the last twelve months of diluted earnings per share (forward P/E about 12.1).
Is Novo Nordisk A S stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 37% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Novo Nordisk A S pay a dividend?
Yes. The dividend yield is about 4.32%, and it has paid dividends for 7 years in our data.
Is Novo Nordisk A S a good stock to buy?
We do not give buy or sell advice. Novo Nordisk A S scores 3.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.